Business Context and Reporting Period
This Form 8-K Current Report is filed by Pieris Pharmaceuticals, Inc. (PIRS), an emerging growth company incorporated in Nevada. The report covers events occurring between August 29, 2019, and September 3, 2019, primarily concerning significant changes to the company's senior management team and corporate bylaws.
Key Financial Metrics
This filing is a current report regarding corporate governance and personnel changes. It does not provide financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. Investors should refer to the company's most recent Form 10-Q or 10-K for financial performance details.
Material Changes
- Departure of CFO and Treasurer: Dr. Allan Reine resigned from his positions as Chief Financial Officer (CFO) and Treasurer, effective September 13, 2019. He will remain employed through that date to facilitate a transition.
- Appointment of New Treasurer and Principal Financial Officer: Mr. Thomas Bures, previously Vice President, Finance, was appointed Treasurer and designated as the Company's principal financial and accounting officer, effective September 13, 2019.
- Appointment of Chief Scientific Officer: Dr. Hitto Kaufmann was appointed Senior Vice President and Chief Scientific Officer, effective August 30, 2019. He will lead drug discovery, protein engineering, and biomanufacturing activities, serving as site head for the Freising, Germany facility.
- Bylaw Amendment: The Board amended the Company's bylaws to remove the requirement to maintain an officer with the specific title "Chief Financial Officer."
Outlook, Risks, and Management Commentary
The filing indicates a strategic shift in leadership to support the company's research and development infrastructure. Dr. Kaufmann brings extensive experience from Sanofi and Boehringer Ingelheim, specifically in biologics manufacturing and the integration of artificial intelligence into drug discovery. Mr. Bures assumes day-to-day leadership of internal financial functions. The company has entered into indemnification agreements with both new officers to cover expenses related to their service.
Key Facts for Investor Verification
- Verify the effective dates of the leadership transitions (August 30, 2019, for Dr. Kaufmann; September 13, 2019, for Mr. Bures).
- Confirm the removal of the "Chief Financial Officer" title requirement in the amended bylaws (Exhibit 3.1).
- Review the press release (Exhibit 99.1) for additional context on the strategic rationale for these appointments.
- Note that Dr. Reine will provide transition services post-resignation.